Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.55 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | NAAA | Q02083 | 3/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3466518 | 0.93 | HTR3A (0.61) | MIFHTR3ANAAAMAOAMAOB | |
| SCHEMBL3466033 | 0.84 | HIF1A (0.50) | MIFHTR3AMAOAMAOB | |
| SCHEMBL9819844 | 0.79 | NAAA (0.64) | MIFHTR3ANAAAMAOAMAOB | |
| SCHEMBL9819842 | 0.79 | NAAA (0.64) | MIFHTR3ANAAAMAOAMAOB | |
| SCHEMBL9819828 | 0.79 | NAAA (0.64) | MIFHTR3ANAAAMAOAMAOB | |
| SCHEMBL9819781 | 0.79 | NAAA (0.64) | MIFHTR3ANAAAMAOAMAOB | |
| SCHEMBL9819790 | 0.79 | NAAA (0.64) | MIFHTR3ANAAAMAOAMAOB | |
| SCHEMBL9819738 | 0.79 | NAAA (0.64) | MIFHTR3ANAAAMAOAMAOB | |
| SCHEMBL451456 | 0.78 | MAOA (0.74) | MAOAMAOBSIGMAR1L3MBTL1 | |
| SCHEMBL8892950 | 0.77 | NAAA (0.62) | MIFHTR3ANAAAMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767690-B2 | Amino alcohol derivatives and their use as renin inhibitor | NOVARTIS AG (CH) | 2010-08-03 | — | — | US | disclosed |
| US-20090118281-A1 | Amino Alcohol Derivatives And Their Use As Renin Inhibitor | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
| US-20070021400-A1 | Amino alcohols as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-01-25 | — | — | US | disclosed |
| EP-1745776-A1 | Aminoalcohols as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-01-24 | — | — | EP | disclosed |
| EP-1711456-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR USE AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005070870-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR USE AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| US-5719141-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0702004-A2 | 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amid derivatives | CIBA-GEIGY AG (CH) | 1996-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118281-A1 | Amino Alcohol Derivatives And Their Use As Renin Inhibitor | REN, AGTR1, ADH1A | MIF 3323/4885HTR3A 2431/4885NAAA 2432/4885 |
| US-20070021400-A1 | Amino alcohols as therapeutic compounds | CTSL, CTSD, CTSS | MIF 4454/4885HTR3A 2666/4885NAAA 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.